Range Financial Group LLC Trims Stock Position in Novo Nordisk A/S $NVO

Range Financial Group LLC cut its position in Novo Nordisk A/S (NYSE:NVO) by 75.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,242 shares of the company’s stock after selling 28,269 shares during the quarter. Range Financial Group LLC’s holdings in Novo Nordisk A/S were worth $470,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of NVO. Martin Capital Partners LLC raised its holdings in shares of Novo Nordisk A/S by 53.8% in the 3rd quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock valued at $6,524,000 after acquiring an additional 41,129 shares in the last quarter. Smith Chas P & Associates PA Cpas grew its holdings in shares of Novo Nordisk A/S by 105.3% during the third quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company’s stock worth $22,497,000 after purchasing an additional 207,959 shares in the last quarter. Clifford Swan Investment Counsel LLC increased its position in shares of Novo Nordisk A/S by 13.7% in the third quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock worth $17,267,000 after purchasing an additional 37,453 shares during the last quarter. Markel Group Inc. increased its position in shares of Novo Nordisk A/S by 4.9% in the third quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock worth $131,436,000 after purchasing an additional 110,061 shares during the last quarter. Finally, Cantor Fitzgerald Investment Advisors L.P. purchased a new stake in Novo Nordisk A/S in the third quarter valued at approximately $1,294,000. 11.54% of the stock is owned by institutional investors.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Company-initiated share repurchase programme — Novo Nordisk confirmed its ongoing buyback (part of up to DKK 15 billion over 12 months, programme started 4 Feb). Buybacks reduce float and are direct shareholder-return support. Share repurchase programme
• Positive Sentiment: High-profile endorsement/coverage — Jim Cramer named NVO among weight‑loss/GLP‑1 picks and media pieces highlight this, which can spur retail interest and short‑term buying. Jim Cramer buyer coverage
• Positive Sentiment: Analyst/idea pieces argue the stock remains an attractive opportunity — at least one Seeking Alpha write‑up reiterates a longer‑term bullish case, which may attract value/long investors amid the pullback. Seeking Alpha analysis
• Neutral Sentiment: Mars CEO named a board observer — Poul Weihrauch will be a board observer at Novo Nordisk; notable for industry ties and governance visibility but unlikely to be an immediate earnings driver. Mars CEO board observer
• Neutral Sentiment: Spike in investor searches/attention — Zacks/Yahoo note heavy search activity on NVO, reflecting elevated retail interest but not necessarily new fundamentals. Investor search activity
• Neutral Sentiment: Sector and market flow context — broader pharma/European ADR coverage (Pfizer/GSK sector pieces, European ADR trading) may be influencing relative flows into/away from large-cap pharma names like NVO. Pharma sector coverage
• Negative Sentiment: Weak recent share performance / valuation concerns — analyst write‑ups highlight negative returns over recent periods and fading momentum, raising questions about near‑term catalysts and putting downward pressure on the stock. Valuation and performance assessment

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Jefferies Financial Group raised shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Citigroup began coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 27th. They set a “neutral” rating on the stock. Morgan Stanley upgraded shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price for the company in a research report on Tuesday, March 3rd. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. Finally, Argus restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Four equities research analysts have rated the stock with a Buy rating, nineteen have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Stock Down 2.1%

Shares of NVO opened at $35.28 on Tuesday. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $81.44. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The stock has a 50 day simple moving average of $45.38 and a two-hundred day simple moving average of $50.29. The firm has a market cap of $157.53 billion, a P/E ratio of 10.17, a P/E/G ratio of 8.52 and a beta of 0.74.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The firm had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. On average, analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The firm also recently announced a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be given a $1.2751 dividend. This represents a yield of 723.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 23.63%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.